Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source
Articles > Article · 2017
Authors: Hadiye ŞİRİN, Pierre Amarenco, Gregory W. Albers, Hans Denison, J. Donald Easton, Scott R. Evans, Peter Held, Michael D. Hill, Jenny Jonasson, Scott E. Kasner, Per Ladenvall, Kazuo Minematsu, Carlos A. Molina, Yongjun Wang, K. S. Lawrence Wong, S. Claiborne Johnston
STROKE, Journal Indexed in SCI Expanded, International, 2017, vol 48, pp 2480-2492
DOI: 10.1161/strokeaha.117.017217
Summary
Background and Purpose-Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis.